Table 4.
Occurrence rates and ranks for subtypes of adverse events according to treatments for Helicobacter pylori eradication
| Treatments | Abdominal or epigastric pain | Alteration in taste | Headache with or without vomiting | Diarrhoea | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean occurrence rate (95% CrI) | Mean rank* (95% CrI) | Mean occurrence rate (95% CrI) | Mean rank* (95% CrI) | Mean occurrence rate (95% CrI) | Mean rank* (95% CrI) | Mean occurrence rate (95% CrI) | Mean rank* (95% CrI) | ||||
| 7 days triple | 0.05 (0.03 to 0.07) | 8.84 (7 to 12) | 0.08 (0.06 to 0.11) | 7.16 (5 to 10) | 0.03 (0.02 to 0.04) | 5.67 (3 to 8) | 0.08 (0.07 to 0.10) | 9.07 (6 to 12) | |||
| 7 days concomitant | 0.14 (0.03 to 0.39) | 13.01 (6 to 14) | 0.30 (0.06 to 0.74) | 13.01 (5 to 14) | NA | NA | 0.12 (0.04 to 0.27) | 10.96 (3 to 14) | |||
| 10 or 14 days sequential | 0.05 (0.03 to 0.08) | 9.45 (7 to 12) | 0.09 (0.05 to 0.14) | 8.29 (5 to 11) | 0.05 (0.02 to 0.10) | 9.22 (6 to 12) | 0.07 (0.04 to 0.09) | 5.62 (3 to 9) | |||
| 10 or 14 days triple | 0.06 (0.03 to 0.09) | 10.93 (8 to 13) | 0.12 (0.07 to 0.18) | 11.22 (9 to 13) | 0.04 (0.02 to 0.08) | 7.98 (5 to 11) | 0.09 (0.06 to 0.12) | 9.34 (6 to 12) | |||
| 10 or 14 days bismuth | 0.06 (0.04 to 0.10) | 11.77 (8 to 14) | 0.05 (0.02 to 0.08) | 2.40 (1 to 5) | 0.08 (0.03 to 0.17) | 11.51 (9 to 13) | 0.07 (0.04 to 0.12) | 7.11 (3 to 13) | |||
| 7 days bismuth | 0.06 (0.03 to 0.11) | 10.99 (6 to 14) | 0.05 (0.03 to 0.09) | 3.56 (1 to 8) | 0.05 (0.02 to 0.11) | 9.46 (5 to 13) | 0.11 (0.07 to 0.18) | 11.88 (6 to 14) | |||
| 10 or 14 days concomitant | 0.06 (0.03 to 0.10) | 10.31 (6 to 14) | 0.10 (0.05 to 0.17) | 8.91 (4 to 13) | 0.06 (0.02 to 0.16) | 9.62 (4 to 13) | 0.09 (0.05 to 0.14) | 9.29 (4 to 14) | |||
| 7 days probiotic | 0.03 (0.02 to 0.05) | 5.85 (4 to 10) | 0.07 (0.04 to 0.12) | 6.02 (3 to 11) | 0.01 (0.00 to 0.06) | 3.15 (1 to 10) | 0.05 (0.03 to 0.08) | 3.36 (1 to 7) | |||
| 10 or 14 days probiotic | 0.02 (0.01 to 0.03) | 3.41 (1 to 6) | 0.17 (0.08 to 0.31) | 12.72 (9 to 14) | 0.01 (0.00 to 0.03) | 1.82 (1 to 6) | 0.03 (0.01 to 0.05) | 1.29 (1 to 3) | |||
| 7 days ranitidine bismuth | 0.01 (0.00 to 0.04) | 1.91 (1 to 6) | 0.08 (0.04 to 0.13) | 6.11 (2 to 12) | 0.07 (0.00 to 0.33) | 7.47 (1 to 13) | 0.09 (0.04 to 0.17) | 9.59 (3 to 14) | |||
| 10 or 14 days ranitidine bismuth | 0.01 (0.00 to 0.03) | 1.94 (1 to 5) | 0.09 (0.04 to 0.17) | 8.28 (3 to 13) | 0.02 (0.00 to 0.09) | 4.68 (1 to 11) | 0.07 (0.03 to 0.12) | 6.18 (2 to 13) | |||
| 7 days levofloxacin | 0.04 (0.02 to 0.07) | 7.11 (4 to 12) | 0.04 (0.02 to 0.06) | 1.68 (1 to 4) | 0.03 (0.01 to 0.06) | 5.96 (2 to 11) | 0.05 (0.03 to 0.08) | 3.47 (1 to 8) | |||
| 10 or 14 days levofloxacin | 0.03 (0.01 to 0.06) | 4.97 (2 to 11) | 0.07 (0.03 to 0.14) | 4.91 (1 to 11) | 0.02 (0.00 to 0.06) | 3.73 (1 to 9) | 0.11 (0.05 to 0.19) | 11.17 (5 to 14) | |||
| 14 days hybrid | 0.02 (0.01 to 0.06) | 4.52 (1 to 11) | 0.13 (0.05 to 0.24) | 10.74 (4 to 14) | 0.20 (0.01 to 0.86) | 10.73 (2 to 13) | 0.08 (0.02 to 0.19) | 6.68 (1 to 14) | |||
CrI=credible interval; NA=not applicable.
*Rank was derived from occurrence rate of values for adverse event subtypes for all studies, 1=best tolerance.